Cargando…

Dasatinib modulates sensitivity to pemetrexed in malignant pleural mesothelioma cell lines

BACKGROUND: Thymidylate synthase (TS), one of the key enzymes for thymidine synthesis, is a target of pemetrexed (PEM), a key agent for the systemic therapy of malignant pleural mesothelioma (MPM) and its overexpression has been correlated to PEM-resistance. In MPM, experimental data report activati...

Descripción completa

Detalles Bibliográficos
Autores principales:	Monica, Valentina, Iacono, Marco Lo, Bracco, Enrico, Busso, Simone, Blasio, Laura Di, Primo, Luca, Peracino, Barbara, Papotti, Mauro, Scagliotti, Giorgio
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Impact Journals LLC 2016
Materias:	Research Paper
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5363531/ https://www.ncbi.nlm.nih.gov/pubmed/27391433 http://dx.doi.org/10.18632/oncotarget.10428

Ejemplares similares

Pathological Characterization of Tumor Immune Microenvironment (TIME) in Malignant Pleural Mesothelioma
por: Napoli, Francesca, et al.
Publicado: (2021)

Review of pemetrexed in combination with cisplatin for the treatment of malignant pleural mesothelioma
por: Goudar, Ranjit K
Publicado: (2008)

Upregulation of Thymidylate Synthase Induces Pemetrexed Resistance in Malignant Pleural Mesothelioma
por: Sato, Yuzo, et al.
Publicado: (2021)

Evaluation of the Preclinical Efficacy of Lurbinectedin in Malignant Pleural Mesothelioma
por: Anobile, Dario P., et al.
Publicado: (2021)

Aurora Kinase A expression is associated with lung cancer histological-subtypes and with tumor de-differentiation
por: Lo Iacono, Marco, et al.
Publicado: (2011)

Polymorphisms in folate pathway and pemetrexed treatment outcome in patients with malignant pleural mesothelioma
por: Goricar, Katja, et al.
Publicado: (2014)

Pemetrexed-loaded nanoparticles targeted to malignant pleural mesothelioma cells: an in vitro study
por: Cova, Emanuela, et al.
Publicado: (2019)

Antagonist of Growth Hormone-Releasing Hormone Potentiates the Antitumor Effect of Pemetrexed and Cisplatin in Pleural Mesothelioma
por: Gesmundo, Iacopo, et al.
Publicado: (2022)

Phase II study of pemetrexed and carboplatin plus bevacizumab as first-line therapy in malignant pleural mesothelioma
por: Ceresoli, G L, et al.
Publicado: (2013)

SKP2 drives the sensitivity to neddylation inhibitors and cisplatin in malignant pleural mesothelioma
por: Salaroglio, Iris Chiara, et al.
Publicado: (2022)

In Vitro Characterization of Cisplatin and Pemetrexed Effects in Malignant Pleural Mesothelioma 3D Culture Phenotypes
por: Papazoglou, Eleftherios D., et al.
Publicado: (2019)

CD157 enhances malignant pleural mesothelioma aggressiveness and predicts poor clinical outcome
por: Ortolan, Erika, et al.
Publicado: (2014)

The role of folate receptor alpha (FRα) in the response of malignant pleural mesothelioma to pemetrexed-containing chemotherapy
por: Nutt, J E, et al.
Publicado: (2010)

The effectiveness and safety of platinum-based pemetrexed and platinum-based gemcitabine treatment in patients with malignant pleural mesothelioma
por: Ak, Guntulu, et al.
Publicado: (2015)

Co-existing pericardial and pleural malignant mesothelioma responding well to nedaplatin and pemetrexed: a case report
por: Wu, Mindan, et al.
Publicado: (2023)

JME-001 phase II trial of first-line combination chemotherapy with cisplatin, pemetrexed, and nivolumab for unresectable malignant pleural mesothelioma
por: Miyamoto, Yosuke, et al.
Publicado: (2021)

Pemetrexed plus carboplatin in elderly patients with malignant pleural mesothelioma: combined analysis of two phase II trials
por: Ceresoli, G L, et al.
Publicado: (2008)

Bevacizumab plus cisplatin/pemetrexed then bevacizumab alone for unresectable malignant pleural mesothelioma: A Japanese safety study
por: Nakano, Takashi, et al.
Publicado: (2020)

Malignant pleural mesothelioma
por: Rao, Sukhesh
Publicado: (2009)

Micro-RNA-215 and -375 regulate thymidylate synthase protein expression in pleural mesothelioma and mediate epithelial to mesenchymal transition
por: Napoli, Francesca, et al.
Publicado: (2022)

Correction to: Micro-RNA-215 and -375 regulate thymidylate synthase protein expression in pleural mesothelioma and mediate epithelial to mesenchymal transition
por: Napoli, Francesca, et al.
Publicado: (2022)

Folic acid phenotype (FAP) is a superior biomarker predicting response to pemetrexed-based chemotherapy in malignant pleural mesothelioma
por: Mairinger, Fabian Dominik, et al.
Publicado: (2017)

Pemetrexed Maintenance Therapy Following Bevacizumab-Containing First-Line Chemotherapy in Advanced Malignant Pleural Mesothelioma: A Case Report and Literatures Review
por: Jing, Xu-Quan, et al.
Publicado: (2016)

Malignant pleural mesothelioma with resolution of pleural effusion
por: Nishida, Sayaka, et al.
Publicado: (2023)

Malignant pleural mesothelioma in Italy
por: Bianchi, Claudio, et al.
Publicado: (2009)

Heterogeneity in Malignant Pleural Mesothelioma
por: Oehl, Kathrin, et al.
Publicado: (2018)

Immunotherapy in Malignant Pleural Mesothelioma
por: de Gooijer, Cornedine J., et al.
Publicado: (2020)

Malignant pleural mesothelioma: an update
por: Hajj, Glaucia N. M., et al.
Publicado: (2021)

Malignant pleural mesothelioma in situ
por: Ando, Kohei, et al.
Publicado: (2022)

Metformin Induces Apoptosis and Inhibits Notch1 in Malignant Pleural Mesothelioma Cells
por: Rossini, Marika, et al.
Publicado: (2021)

Successful desensitization of pemetrexed-induced anaphylaxis in a patient with malignant mesothelioma
por: Youk, Jeonghwan, et al.
Publicado: (2017)

Diagnostic and Therapeutic Challenges of Malignant Pleural Mesothelioma
por: Moro, Jacopo, et al.
Publicado: (2022)

Picropodophyllin inhibits the growth of pemetrexed-resistant malignant pleural mesothelioma via microtubule inhibition and IGF-1R-, caspase-independent pathways
por: Sun, Rong, et al.
Publicado: (2022)

Feasibility of Tumor Treating Fields with Pemetrexed and Platinum-Based Chemotherapy for Unresectable Malignant Pleural Mesothelioma: Single-Center, Real-World Data
por: Kutuk, Tugce, et al.
Publicado: (2022)

Alvopem(®) (pemetrexed) safety assessment in patients with non-small cell lung cancer or malignant pleural mesothelioma: a post-marketing surveillance
por: Seifi, Sharareh, et al.
Publicado: (2023)

Antagonists of growth hormone-releasing hormone (GHRH) inhibit the growth of human malignant pleural mesothelioma
por: Villanova, Tania, et al.
Publicado: (2019)

Phase II trial of neoadjuvant pemetrexed plus cisplatin followed by surgery and radiation in the treatment of pleural mesothelioma
por: Federico, Rea, et al.
Publicado: (2013)

New Perspectives on Diagnosis and Therapy of Malignant Pleural Mesothelioma
por: Rossini, Marika, et al.
Publicado: (2018)

Thoracoscopy in Pleural Malignant Mesothelioma Diagnosis
por: Tassi, G. F., et al.
Publicado: (1997)

Imaging in staging of malignant pleural mesothelioma
por: Truong, Mylene T, et al.
Publicado: (2004)

Cannot write session to /tmp/vufind_sessions/sess_n7u6gqe4fn6jdtpa4u5uv6pc73